THE SIGNIFICANCE OF CIRCULATING SURFACTANT PROTEIN D AND DYSLIPIDEMIA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CORONARY HEART DISEASE AND THEIR COMBINATION.

As it is widely known, cardiovascular diseases represent one of the leading causes of mortality. In the coexistence of chronic obstructive pulmonary disease (COPD), the mortality rate is increasing as well. The research conducted reviews the effect of surfactant protein D on the coronary heart disease and chronic obstructive pulmonary disease.

CESARIAN SECTION - HIGHER RATE AND HIGHER CHALLENGES.

There is evidence that perinatal morbidity and mortality has not changed - caesarean section rate increased and data remained stable and rate of intro and post operative complications was increased. There is another view of the picture: the right of patient to choose mode of delivery and the reality, that the number of patients with prior caesarian section and number patient and physician prefer caesarean section. The following topics are discussed as well: age of pregnant woman, macrosomia and intrauterine growth restriction, malpresentation, multiple gestation, preeclampsia, BMI, role of assisted reproductive technologies, electronic monitoring of fetal heart rate in labor, induction of labor.

[Prospects of stem cells application in patients with ischemic heart disease (review)].

Coronary heart disease (CHD) is the most common cause of human mortality. Despite of recent advances in the management of CHD (drug treatment, coronary angioplasty and stenting, coronary artery bypass surgery) prognostic estimation of this kind of mortality threatens to increase to the year 2030. Major cause of adversity of CHD is decrease in myocardial contractility which leads to heart failure (HF).

[Estimation of effectiveness of the prevention of sudden cardiac death in patients with myocardial infarction].

On the basis of open, randomized, inspected trial during 1 year period, the effectiveness of inclusion in the standard treatment of beta blockers, metoprolol and Carvedilol for prophylaxis of sudden cardiac death has been investigated. 112 patients with a myocardial infarction in the age of from 45 till 70 years from the contingent of the IV hospital of Tbilisi were included in the trial. Absolute and relative risk reductions were defined.

[Effect of thrombolytic therapy with intravenous streptokinase on the size of myocardial infarction estimated by the ECG QRS score system].

The impact of short-term intravenous large dose streptokinase injection on the myocardial infarction size estimated by a QRS score system was studied in 57 patients with primary myocardial infarction admitted to hospital at least 6 hours following the onset of the disease. There was a lower myocardial infarction size despite its localization and the time of treatment initiation when thrombolysis was successful, as evidenced by non-invasive criteria. The reliability of the QRS score system used to estimate the myocardial infarction size increased when the patients with anterior or inferior myocardial infarction and those with successful and unsuccessful systemic streptokinase thrombolysis.

[Relation between left-ventricular insufficiency and necrotic mass in myocardial infarction, determined by analysis of the QRS complex].

A noninvasive method, based on the analysis of QRS parameters from 10 of 12 standard ECG leads, was used to assess the size of necrosis in patients with acute myocardial infarction. A close correlation between anterior left-ventricular myocardial infarction weight and congestive left-ventricular insufficiency has been demonstrated. No such correlation was demonstrated for inferior myocardial infarction.

[Anti-angina effectiveness of sustak and obzidan in the acute period of myocardial infarct].

Sustak and obsidan were given separately and in combination to 99 patients with acute myocardial infarction and frequent attacks of angina pectoris. With the use of these agents the attacks of angina pectoris were very rare. The course of the disease and the prognosis were more favourable in the group of patients treated with anti-anginal agents than in the control group (100 patients).